Real-world Evidence Epic EHR data: Cancer screenings nosedive in 2021 despite easing of COVID restrictions September 17, 2021Vol.47 No.34By Matthew Bin Han Ong
Conversation with The Cancer Letter COTA’s Miruna Sasu: I left pharma to “turn the spigot on” in the real-world data industry June 11, 2021Vol.47 No.23By Matthew Bin Han Ong
FreeTrials & Tribulations Precision oncology must evolve to address health disparities June 04, 2021Vol.47 No.22By Brandon Mahal and Jeffrey Venstrom
Real-world Evidence Study of NSCLC, melanoma outcomes points to surrogacy between real-world endpoints and clinical trial endpoints September 25, 2020Vol.46 No.36By Matthew Bin Han Ong
Prostate cancer patients aren’t getting testosterone suppression injections on timePayment policies blamed for non-compliance with treatment guidelines July 24, 2020Vol.46 No.30By Matthew Bin Han Ong
COVID-19 & CancerFree COVID-19 vs. community oncology: Flatiron’s data provides first damage assessment May 01, 2020Vol.46 No.18By Matthew Bin Han Ong
FreeReal-world Evidence Real-world evidence at a glance: How a collaboration of “frenemies” produced common definitions for real-world endpoints November 22, 2019Vol.45 No.44By Matthew Bin Han Ong
Free Real-world data, evidence should be leveraged in clinical research to better include and ultimately treat larger patient populations October 18, 2019Vol.45 No.39By Sarah Alwardt
Free Oncologists quickly react to label changes for immunotherapies, a study by Penn, Flatiron shows September 27, 2019Vol.45 No.36By Matthew Bin Han Ong
Challenges to leveraging real-world evidence for FDA approval September 20, 2019Vol.45 No.35By Ash Malik
